

**Mega Lifesciences Public Company Limited
and its Subsidiaries**

Interim financial statements
for the three-month period ended
31 March 2015

and

Independent auditor's report on
review of interim financial information

Independent Auditor’s Report on Review of Interim Financial Information

To the Board of Directors of Mega Lifesciences Public Company Limited

I have reviewed the accompanying consolidated and separate statements of financial position of Mega Lifesciences Public Company Limited and its subsidiaries, and of Mega Lifesciences Public Company Limited, respectively, as at 31 March 2015; the consolidated and separate statements of comprehensive income, changes in equity and cash flows for the three-month period ended 31 March 2015; and condensed notes (“interim financial information”). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34, “Interim Financial Reporting”. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of Review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34, “Interim Financial Reporting”.

(Orawan Chuhakitpaisan)
Certified Public Accountant
Registration No. 6105

KPMG Phoomchai Audit Ltd.
Bangkok
12 May 2015

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of financial position

	Note	Consolidated financial statements		Separate financial statements	
		31 March 2015 (Unaudited)	31 December 2014	31 March 2015 (Unaudited)	31 December 2014
<i>(in thousand Baht)</i>					
Assets					
Current assets					
Cash and cash equivalents		332,548	340,634	105,443	95,521
Current investments	4	939,314	433,832	939,314	432,775
Trade accounts receivable	3, 5	2,115,782	2,116,051	1,242,922	1,173,501
Other receivables	3	215,757	181,595	83,136	92,733
Short-term loan to related party	3	-	-	-	30,000
Inventories		1,614,759	1,649,471	463,407	438,213
Advances to suppliers and distributors		138,587	128,667	46,038	40,095
Total current assets		5,356,747	4,850,250	2,880,260	2,302,838
Non-current assets					
Investments in associate	6	-	-	-	-
Investments in subsidiaries	7	-	-	62,379	59,923
Other long-term investments	4	-	506,539	-	506,539
Property, plant and equipment	8	978,247	980,141	610,090	620,959
Intangible assets		232,417	230,211	187,703	187,912
Deferred tax assets	9	95,584	93,416	25,077	21,302
Other non-current assets		73,361	71,295	64,504	62,720
Total non-current assets		1,379,609	1,881,602	949,753	1,459,355
Total assets		6,736,356	6,731,852	3,830,013	3,762,193

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of financial position

	Note	Consolidated		Separate	
		financial statements		financial statements	
		31 March 2015 (Unaudited)	31 December 2014	31 March 2015 (Unaudited)	31 December 2014
<i>(in thousand Baht)</i>					
Liabilities and equity					
Current liabilities					
Bank overdrafts and short-term					
loans from financial institutions		365,249	354,188	232,809	262,865
Trade accounts payable	3, 10	1,410,209	1,403,926	151,567	154,488
Other payables		224,006	265,396	17,450	12,089
Short-term loan from and interest					
payable to related party	3	-	-	3,210	2,543
Current portion of long-term loans					
from financial institutions		74,458	75,392	43,691	44,239
Current portion of finance lease liabilities		185	198	77	75
Income tax payable		72,810	55,497	21,509	13,720
Accrued expenses		337,918	366,242	46,917	50,901
Total current liabilities		2,484,835	2,520,839	517,230	540,920
Non-current liabilities					
Long-term loans from financial institutions		117,141	137,173	76,067	87,795
Finance lease liabilities		138	185	49	69
Deferred tax liabilities	9	2,183	2,877	-	-
Employee benefit obligation		92,629	90,111	59,421	56,783
Other non-current liabilities		2,357	2,405	-	-
Total non-current liabilities		214,448	232,751	135,537	144,647
Total liabilities		2,699,283	2,753,590	652,767	685,567

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of financial position

	Note	Consolidated		Separate	
		financial statements		financial statements	
		31 March 2015 (Unaudited)	31 December 2014	31 March 2015 (Unaudited)	31 December 2014
<i>(in thousand Baht)</i>					
Equity					
Share capital:					
Authorised share capital		436,951	436,951	436,951	436,951
Issued and paid-up share capital		432,625	432,625	432,625	432,625
Additional paid in capital:					
Premium on ordinary shares		2,138,104	2,138,104	2,138,104	2,138,104
Warrants	11	11,244	8,431	11,244	8,431
Retained earnings					
Appropriated					
Legal reserve		49,088	49,088	43,695	43,695
Corporate social responsibility reserve	12	11,600	10,000	11,600	10,000
Unappropriated		1,611,619	1,507,232	539,978	443,771
Other components of equity		(217,174)	(167,200)	-	-
Equity attributable to owners					
of the Company		4,037,106	3,978,280	3,177,246	3,076,626
Non-controlling interests		(33)	(18)	-	-
Total equity		4,037,073	3,978,262	3,177,246	3,076,626
Total liabilities and equity		6,736,356	6,731,852	3,830,013	3,762,193

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries
Statement of comprehensive income (Unaudited)

	Note	Consolidated financial statements		Separate financial statements	
		Three-month period ended 31 March		Three-month period ended 31 March	
		2015	2014	2015	2014
<i>(in thousand Baht)</i>					
Income					
Revenue from sales of goods and rendering of services	13	1,803,622	1,705,251	522,149	522,577
Investment income	6, 7	7,964	4,568	7,927	306,452
Other income		7,359	4,496	3,572	2,383
Total income		1,818,945	1,714,315	533,648	831,412
Expenses					
Cost of sales of goods and rendering of services		1,058,431	1,041,978	294,479	324,603
Selling expenses		371,022	355,294	59,337	60,290
Administrative expenses		233,153	231,397	62,206	56,530
Net foreign exchange loss		28,160	20,100	13,706	1,564
Finance costs		2,495	4,838	1,589	3,079
Total expenses		1,693,261	1,653,607	431,317	446,066
Profit before income tax expense		125,684	60,708	102,331	385,346
Income tax expense	14	(19,213)	(4,167)	(4,024)	(5,317)
Profit for the period		106,471	56,541	98,307	380,029
Other comprehensive income					
<i>Item that will never be reclassified to profit or loss</i>					
Defined benefit plan actuarial losses		-	(822)	-	(4,300)
<i>Item that is or may be reclassified to profit or loss</i>					
Foreign currency translation differences for foreign operations		(49,973)	5,633	-	-
Other comprehensive income (loss) for the period, net of income tax		(49,973)	4,811	-	(4,300)
Total comprehensive income for the period		56,498	61,352	98,307	375,729
Profit attributable to:					
Owners of the Company		106,487	56,578	98,307	380,029
Non-controlling interests		(16)	(37)	-	-
Profit for the period		106,471	56,541	98,307	380,029
Total comprehensive income attributable to:					
Owners of the Company		56,513	61,387	98,307	375,729
Non-controlling interests		(15)	(35)	-	-
Total comprehensive income for the period		56,498	61,352	98,307	375,729
Basic and diluted earnings per share (in Baht)	15	0.12	0.07	0.11	0.44

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of changes in equity (Unaudited)

	Consolidated financial statements								
	Issued and paid-up share capital	Share premium	Retained earnings		Other component of equity		Equity attributable to owners of the Company	Non-controlling interests	Total equity
			Legal reserve	Unappropriated	Currency translation differences	Total other components of equity			
<i>(in thousand Baht)</i>									
Three-month period ended 31 March 2014									
Balance at 1 January 2014	432,624	2,138,104	49,088	1,212,726	(139,981)	(139,981)	3,692,561	12	3,692,573
Transactions with owners, recorded directly in equity									
<i>Contributions by and distributions to owners of the Company</i>									
Dividends to owners of the Company	-	-	-	(22)	-	-	(22)	-	(22)
Total transactions with owners, recorded directly in equity	-	-	-	(22)	-	-	(22)	-	(22)
Comprehensive income for the period									
Profit	-	-	-	56,578	-	-	56,578	(37)	56,541
Other comprehensive income	-	-	-	(822)	5,631	5,631	4,809	2	4,811
Total comprehensive income for the period	-	-	-	55,756	5,631	5,631	61,387	(35)	61,352
Balance at 31 March 2014	432,624	2,138,104	49,088	1,268,460	(134,350)	(134,350)	3,753,926	(23)	3,753,903

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of changes in equity (Unaudited)

		Consolidated financial statements										
		Retained earnings					Other component of equity					
		Issued and paid-up share capital	Share premium	Warrants	Legal reserve	Corporate social responsibility reserve	Unappropriated	Currency translation differences	Total other components of equity	Equity attributable to owners of the Company	Non-controlling interests	Total equity
<i>Note</i>												
<i>(in thousand Baht)</i>												
Three-month period ended 31 March 2015												
	Balance at 1 January 2015	432,625	2,138,104	8,431	49,088	10,000	1,507,232	(167,200)	(167,200)	3,978,280	(18)	3,978,262
Transactions with owners, recorded directly in equity												
<i>Contributions by and distributions to owners of the Company</i>												
	Share-based payment transactions	-	-	2,813	-	-	-	-	-	2,813	-	2,813
	Total transactions with owners, recorded directly in equity	-	-	2,813	-	-	-	-	-	2,813	-	2,813
Comprehensive income for the period												
	Profit	-	-	-	-	-	106,487	-	-	106,487	(16)	106,471
	Other comprehensive income	-	-	-	-	-	-	(49,974)	(49,974)	(49,974)	1	(49,973)
	Total comprehensive income for the period	-	-	-	-	-	106,487	(49,974)	(49,974)	56,513	(15)	56,498
	Transfer to corporate social responsibility reserve	-	-	-	-	2,100	(2,100)	-	-	-	-	-
	Utilisation of corporate social responsibility reserve	-	-	-	-	(500)	-	-	-	(500)	-	(500)
	Balance at 31 March 2015	432,625	2,138,104	11,244	49,088	11,600	1,611,619	(217,174)	(217,174)	4,037,106	(33)	4,037,073

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of changes in equity (Unaudited)

	Note	Separate financial statements					Total equity	
		Issued and paid-up share capital	Share premium	Warrants	Retained earnings			
					Legal reserve	Corporate social responsibility reserve		Unappropriated
<i>(in thousand Baht)</i>								
Three-month period ended 31 March 2014								
Balance at 1 January 2014		432,624	2,138,104	-	43,695	-	68,931	2,683,354
Comprehensive income for the period								
Profit		-	-	-	-	-	380,029	380,029
Other comprehensive income		-	-	-	-	-	(4,300)	(4,300)
Total comprehensive income for the period		-	-	-	-	-	375,729	375,729
Balance at 31 March 2014		<u>432,624</u>	<u>2,138,104</u>	<u>-</u>	<u>43,695</u>	<u>-</u>	<u>444,660</u>	<u>3,059,083</u>
Three-month period ended 31 March 2015								
Balance at 1 January 2015		432,625	2,138,104	8,431	43,695	10,000	443,771	3,076,626
Transactions with owners, recorded directly in equity								
<i>Contributions by and distributions to owners of the Company</i>								
Share-based payment transactions	11	-	-	2,813	-	-	-	2,813
Total transactions with owners, recorded directly in equity		-	-	2,813	-	-	-	2,813
Comprehensive income for the period								
Profit		-	-	-	-	-	98,307	98,307
Other comprehensive income		-	-	-	-	-	-	-
Total comprehensive income for the period		-	-	-	-	-	98,307	98,307
Transfer to corporate social responsibility reserve	12	-	-	-	-	2,100	(2,100)	-
Utilisation of corporate social responsibility reserve	12	-	-	-	-	(500)	-	(500)
Balance at 31 March 2015		<u>432,625</u>	<u>2,138,104</u>	<u>11,244</u>	<u>43,695</u>	<u>11,600</u>	<u>539,978</u>	<u>3,177,246</u>

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of cash flows (Unaudited)

	Consolidated		Separate	
	financial statements		financial statements	
	Three-month period ended		Three-month period ended	
	31 March		31 March	
	2015	2014	2015	2014
	<i>(in thousand Baht)</i>			
<i>Cash flows from operating activities</i>				
Profit for the period	106,471	56,541	98,307	380,029
<i>Adjustments for</i>				
Depreciation	33,458	30,256	17,613	16,114
Amortisation of intangible assets	1,952	1,203	209	210
Allowance for (reversal of) decline in value of inventories	2,419	5,737	(547)	3,047
Investment income	(7,964)	(4,568)	(7,927)	(306,452)
Finance costs	2,495	4,838	1,589	3,079
Allowance for doubtful accounts	914	790	270	-
Unrealised loss on exchange rate	35,458	13,272	17,223	10,984
Gain on disposal of property, plant and equipment	(7)	(553)	-	-
Employee benefit obligations	3,814	3,625	2,638	2,300
Income tax expense	19,213	4,167	4,024	5,317
Share-based payment transactions	2,813	-	357	-
	<u>201,036</u>	<u>115,308</u>	<u>133,756</u>	<u>114,628</u>
<i>Changes in operating assets and liabilities</i>				
Trade accounts receivable	(67,152)	200,150	(88,872)	(277,161)
Other receivables	(28,362)	(139,426)	15,008	(25,437)
Inventories	16,029	(241,030)	(24,647)	(25,130)
Advances to suppliers and distributors	(13,376)	(3,802)	(9,234)	(7,098)
Restricted deposits at financial institutions	-	196	-	196
Other non-current assets	(2,155)	(11,222)	(1,784)	(11,760)
Trade accounts payable	23,909	262,084	(974)	7,430
Other payables	(39,228)	(67,233)	6,142	(10,903)
Accrued expenses	(24,922)	(10,616)	(3,984)	4,090
Utilisation of corporate social responsibility reserve	(500)	-	(500)	-
Employee benefit obligations paid	(208)	-	-	-
Cash generated from (used in) operating activities	<u>65,071</u>	<u>104,409</u>	<u>24,911</u>	<u>(231,145)</u>
Income tax paid	(4,516)	(10,176)	(10)	(48)
Net cash from (used in) operating activities	<u>60,555</u>	<u>94,233</u>	<u>24,901</u>	<u>(231,193)</u>

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries

Statement of cash flows (Unaudited)

	Consolidated		Separate	
	financial statements		financial statements	
	Three-month period ended		Three-month period ended	
	31 March		31 March	
	2015	2014	2015	2014
	<i>(in thousand Baht)</i>			
<i>Cash flows from investing activities</i>				
Interest received	1,015	172	1,091	3,261
Dividend received	-	-	-	300,000
Purchase of property, plant and equipment	(57,586)	(57,265)	(6,775)	(36,022)
Purchase of intangible assets	(4,487)	(5,344)	-	-
Redemption of current investments	1,043	-	-	-
Sale of equipment	3,062	623	-	-
Net cash from (used in) investing activities	(56,953)	(61,814)	(5,684)	267,239
<i>Cash flows from financing activities</i>				
Finance cost paid	(2,484)	(4,995)	(1,579)	(3,200)
Dividends paid	-	(22)	-	-
Finance lease payments	(60)	(98)	(18)	(48)
Increase (decrease) in bank overdrafts and short-term loans from financial institutions	15,102	38,764	(25,422)	184,246
Increase in short-term loans to related parties	-	-	-	(220,000)
Receipt of short-term loan to related party	-	-	30,000	-
Repayment of borrowings	(19,667)	(18,585)	(12,276)	(10,882)
Net cash from (used in) financing activities	(7,109)	15,064	(9,295)	(49,884)
Net increase (decrease) in cash and cash equivalents				
	(3,507)	47,483	9,922	(13,838)
Cash and cash equivalents at 1 January	340,634	1,540,309	95,521	1,119,123
Effect of exchange rate changes on balances held in foreign currency	(4,579)	(3,562)	-	-
Cash and cash equivalents at 31 March	332,548	1,584,230	105,443	1,105,285

The accompanying notes are an integral part of these financial statements.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Note	Contents
1	General information
2	Basis of preparation of the interim financial statements
3	Related parties
4	Other investments
5	Trade accounts receivable
6	Investments in associate
7	Investments in subsidiaries
8	Property, plant and equipment
9	Deferred tax
10	Trade accounts payable
11	Warrants
12	Corporate social responsibility reserve
13	Segment information
14	Income tax expense
15	Earnings per share
16	Commitments and contingent liabilities with non-related parties
17	Events after the reporting period
18	Reclassification of accounts

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

These notes form an integral part of the interim financial statements.

The interim financial statements issued for Thai regulatory reporting purposes are prepared in the Thai language. These English language financial statements have been prepared from the Thai language statutory financial statements, and were approved and authorised for issue by the Board of Directors on 12 May 2015.

1 General information

Mega Lifesciences Public Company Limited, “the Company”, is incorporated in Thailand and has its registered office at No. 384, Moo 4, Bangpoo Industrial Estate, Praksa, Muang - Samutprakarn, Samutprakarn, Thailand.

The Company has representative offices in Vietnam, Uganda, Ukraine and Kenya and representative offices under Mega Lifesciences PTY Limited, a subsidiary, in Sri Lanka, Vietnam, Myanmar, Indonesia, Uzbekistan, Ukraine, Malaysia, Philippines, Kenya, India, Russia, Kazakhstan and Ghana.

The immediate and ultimate holding company during the financial period was Unistretch Limited, which is incorporated in Thailand.

The Company was listed on the Stock Exchange of Thailand on 19 November 2013.

The principal activities of the Group are the manufacture and sale through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast moving consumer goods as well as the provision of distribution services relating to such products.

Details of the Company’s associate and subsidiaries as at 31 March 2015 are given in notes 3, 6 and 7.

2 Basis of preparation of the interim financial statements

(a) Statement of compliance

The interim financial statements are prepared on a condensed basis in accordance with Thai Accounting Standard (TAS) No. 34 (revised 2014) *Interim Financial Reporting*; guidelines promulgated by the Federation of Accounting Professions (FAP); and applicable rules and regulations of the Thai Securities and Exchange Commission.

The interim financial statements are prepared to provide an update on the financial statements for the year ended 31 December 2014. They do not include all of the financial information required for full annual financial statements but focus on new activities, events and circumstances to avoid repetition of information previously reported. Accordingly, these interim financial statements should be read in conjunction with the financial statements of the Company and its subsidiaries for the year ended 31 December 2014.

The accounting policies and methods of computation applied in these interim financial statements are consistent with those applied in the financial statements for the year ended 31 December 2014 except that the Group has adopted all the new and revised TFRS that are effective for annual periods beginning on or after 1 January 2015. The adoption of these new and revised TFRS did not have any material effect on the accounting policies, methods of computation, financial performance or position of the Group.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

(b) Functional and presentation currency

The interim financial statements are presented in Thai Baht, which is the Company's functional currency. All financial information presented in Thai Baht has been rounded to the nearest thousand unless otherwise stated.

(c) Judgements and estimates

The preparation of interim financial statements in conformity with TFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

In preparing these interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial statements for the year ended 31 December 2014.

3 Related parties

For the purposes of these financial statements, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control or joint control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Relationships with an associate and subsidiaries are described in note 6 and 7. Relationships with key management and other related parties were as follows:

Name of entities	Country of incorporation/ nationality	Nature of relationships
Unistretch Limited	Thailand	Ultimate parent of the Group
Al-Mayoni For Trading Services Ltd.	Yemen	Common shareholders
Magnus Pharmaceuticals Ltd.	Yemen	Common shareholders
Ambika Tours Agency Limited	Thailand	Common shareholders and directors
InsurExcellence Insurance Brokers Ltd.	Thailand	Common shareholders and directors
Linaria Chemical (Thailand) Limited	Thailand	Common shareholders and directors
Mechai Pattana School	Thailand	Common Chairman
Key management personnel		Persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of the Group.

The pricing policies for transactions with related parties are explained further below:

Transactions	Pricing policies
Sale of goods and rendering of service	Market price minus margin
Purchase of goods and raw materials	Cost plus margin
Interest income and interest expense	Agreed rates stipulated in the agreements
Other income and other expenses	Contractually agreed prices

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Significant transactions for the three-month periods ended 31 March 2015 and 2014 with related parties were as follows:

<i>Three-month period ended 31 March</i>	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
	<i>(in thousand Baht)</i>			
Subsidiaries				
Sale of goods and rendering of service	-	-	211,790	254,740
Purchase of goods and receiving of service	-	-	8,229	2,840
Commission expense	-	-	5,512	4,735
Interest expense	-	-	10	10
Interest income	-	-	113	2,075
Other income	-	-	66	844
Advertising expense	-	-	5,912	-
Key management personnel				
Key management personnel compensation				
Short-term employee benefits	26,494	17,595	4,038	4,093
Post-employment benefits	331	298	236	206
Expense for employee stock option plan	72	-	72	-
Total key management personnel compensation	26,897	17,893	4,346	4,299
Directors' remuneration	1,860	1,860	1,860	1,860
Other related parties				
Sale of goods	9,024	15,284	9,024	15,284
Purchase of goods and receiving of services	3,729	8,713	1,597	3,532
Donation	500	-	500	-

Balances as at 31 March 2015 and 31 December 2014 with related parties were as follows:

<i>Trade accounts receivable - related parties</i>	Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>			
Subsidiaries	-	-	565,758	549,563
Other related parties	61,784	62,524	61,784	62,524
Total	61,784	62,524	627,542	612,087
Other receivables - related parties				
	Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>			
Subsidiaries	-	-	9,208	33,932
Other related parties	3,040	450	2,801	-
Total	3,040	450	12,009	33,932

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

<i>Loans to related parties</i>	Interest rate		Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 December 2014
<i>Short-term loan</i>	(% per annum)		(in thousand Baht)			
Subsidiary	-	1.65	-	-	-	30,000
Short-term loan to related party			-	-	-	30,000

Movements during the three-month periods ended 31 March 2015 and 2014 of loans to related parties were as follows:

<i>Short-term loans to related parties</i>	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
<i>Three-month period ended 31 March</i>	(in thousand Baht)			
<i>Subsidiary</i>				
At 1 January	-	-	30,000	400,000
Increase	-	-	-	300,000
Decrease	-	-	(30,000)	(80,000)
At 31 March	-	-	-	620,000

<i>Trade accounts payable - related parties</i>	Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	(in thousand Baht)			
Subsidiaries	-	-	30,829	21,108
Total	-	-	30,829	21,108

<i>Other payables - related parties</i>	Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	(in thousand Baht)			
Subsidiaries	-	-	799	-
Other related parties	4,966	481	4,301	-
Total	4,966	481	5,100	-

<i>Loan from and interest payable to related party</i>	Interest rate		Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 December 2014
<i>Short-term loan</i>	(% per annum)		(in thousand Baht)			
Subsidiary	1.30	1.70	-	-	3,210	2,543
Short-term loan from related party			-	-	3,210	2,543

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Movements during the three-month periods ended 31 March 2015 and 2014 of loans from related parties were as follows:

<i>Loan from and interest payable to related parties</i>	Consolidated		Separate	
	financial statements		financial statements	
<i>Three-month period ended 31 March</i>	2015	2014	2015	2014
	<i>(in thousand Baht)</i>			
Short-term loan				
Subsidiary				
At 1 January	-	-	2,543	2,603
Increase	-	-	667	10
At 31 March	-	-	3,210	2,613

Significant agreements with related parties

As at 31 March 2015, the Group had the following significant agreements with related parties.

Commission agreement

The Company entered into a commission agreement with Mega Lifesciences (Australia) Pty. Limited, a subsidiary, whereas Mega Lifesciences (Australia) Pty. Limited grants the Company an exclusive right to market, sell and distribute product namely Nat-C either by itself or through third parties. The Company shall pay the commission at the rate of 25% of the sale value on a quarterly basis. This agreement is effective on 1 January 2015, and shall remain valid till it is changed and shall be co-terminous with the said agreements. The agreement shall be automatically renewed after one year with such terms as the parties may agree.

Loan agreement

On 28 February 2014, the Company entered into a loan agreement with a subsidiary for an amount of Baht 300 million, with an interest rate which the Company pays to the bank in obtaining the loan and at the rate on fixed deposits in case of the Company's repayment to the bank in full. This loan is scheduled to be repaid in installments agreed to by the signing parties within 28 February 2015.

Supply agreement

The Company has a supply agreement with Mega Lifesciences Pty. Limited, a subsidiary, whereby the Company agrees to manufacture and supply the product as per required specification and as per Good Manufacturing Practice (GMP). This agreement is effective on the agreement date and shall be terminated by either party giving at least 30 days notice in writing to the other party.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

4 Other investments

As at 31 March 2015, a fixed deposit at a financial institution of Baht 506.54 million will mature within 12 months. The Company reclassified the investment from non-current investment to current investment.

During the three-month period ended 31 March 2015, a restricted deposit at a financial institution of a subsidiary of Baht 1.06 million was redeemed. The Group reclassified the investment from current investment to cash and cash equivalents.

5 Trade accounts receivable

	<i>Note</i>	Consolidated financial statements		Separate financial statements	
		31 March 2015	31 December 2014	31 March 2015	31 December 2014
		<i>(in thousand Baht)</i>			
Related parties	3	61,784	62,524	627,542	612,087
Other parties		2,062,301	2,062,844	615,650	561,414
Total		2,124,085	2,125,368	1,243,192	1,173,501
Less allowance for doubtful accounts		(8,303)	(9,317)	(270)	-
Net		2,115,782	2,116,051	1,242,922	1,173,501
Bad and doubtful debts expense for the three-month period ended 31 March		914	790	270	-

Aging analyses for trade accounts receivable are as follows:

	Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>			
Related parties				
Within credit terms	29,611	33,314	431,258	531,189
Overdue:				
Less than 3 months	11,469	6,285	137,378	33,221
3 - 6 months	6,285	7,457	21,781	19,891
6 - 12 months	14,419	12,552	28,411	19,643
Over 12 months	-	2,916	8,714	8,143
	61,784	62,524	627,542	612,087

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

	Consolidated		Separate	
	financial statements		financial statements	
	31	31	31	31
	March	December	March	December
	2015	2014	2015	2014
	<i>(in thousand Baht)</i>			
Other parties				
Within credit terms	1,237,303	1,496,552	300,246	388,931
Overdue:				
Less than 3 months	654,337	445,080	240,479	150,974
3 - 6 months	136,437	65,695	68,810	17,872
6 - 12 months	19,726	25,572	5,510	3,130
Over 12 months	14,498	29,945	605	507
	2,062,301	2,062,844	615,650	561,414
<i>Less allowance for</i>				
doubtful accounts	<u>(8,303)</u>	<u>(9,317)</u>	<u>(270)</u>	<u>-</u>
	2,053,998	2,053,527	615,380	561,414
Net	2,115,782	2,116,051	1,242,922	1,173,501

The normal credit term granted by the Group ranges from 30 days to 360 days.

The aging is calculated by counting the age of trade accounts receivable from the day the Group delivers products and issues an invoice to the local importers or distributors. However, revenue is not recognised until such local importers or distributors complete the sale of products to the end consumers. Consequently, there is a time lag between when the aging commences and when the revenue is recognised. This results in an apparent high level of overdue trade accounts receivable.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

6 Investments in associate

Investments in an associate as at 31 March 2015 and 31 December 2014 were as follows:

		Consolidated financial statements								
Type of business	Country of Incorporation	Ownership interest		Paid-up capital		Cost		Equity		
		31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 December 2014	
		(%)				(in thousand Baht)				
Indirect associate										
Mega Product (Yemen) Limited	Distribution and marketing	Yemen	48.99	48.99	2,476	2,476	1,213	1,213	-	-
Total							1,213	1,213	-	-

The Group has not recognised losses relating to certain investments accounted for using the equity method where its share of losses exceeds the carrying amount of those investments. As at 31 March 2015, the Group's cumulative share of unrecognised losses was Baht 5.89 million (31 December 2014: Baht 5.17 million), of which the Group's share of losses for the three-month period ended 31 March 2015 was Baht 0.79 million (31 March 2014: profit of Baht 0.39 million). The Group has no obligation in respect of these losses.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

7 Investments in subsidiaries

	Separate financial statements	
	2015	2014
	<i>(in thousand Baht)</i>	
At 1 January	59,923	52,162
Increase	2,456	-
At 31 March	<u>62,379</u>	<u>52,162</u>
At 31 December		<u>59,923</u>

Employee stock option plan

Additional investments in subsidiaries of Baht 2.5 million resulted from Employee Stock Option Plan granted to employees of the Company's subsidiaries (see note 11).

Additional investment in indirect subsidiaries

During March 2015, Mega Lifesciences PTY Limited (Thailand), a subsidiary, made an additional investment of Baht 38.9 million in the issued and paid up capital of Mega Lifesciences (Australia) Pty. Limited, an indirect subsidiary of the Company, in order to expand the business.

During February 2014, Mega Lifesciences PTY Limited (Thailand), a subsidiary, made an additional investment of Baht 45.0 million in issued and paid up capital of Mega Lifesciences (Vietnam) Limited, an indirect subsidiary of the Company, in order to expand the business.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Investments in subsidiaries as at 31 March 2015 and 31 December 2014 and dividend income from those investments for the three-month periods ended 31 March 2015 and 2014 were as follows:

	Type of business	Country of incorporation	Ownership interest		Paid-up capital		Cost		Dividend income	
			31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 March 2014
<i>Direct subsidiaries</i>										
Mega Lifesciences PTY Limited	Branded products and distribution business	Thailand	99.99	99.99	50,000	50,000	60,048	57,592	-	300,000
Natural Health Foods Limited	Branded products business	Thailand	99.99	99.99	2,000	2,000	1,996	1,996	-	-
Mega We Care Limited	Branded products business	Thailand	99.96	99.96	170	170	170	170	-	-
Mega Lifesciences Limited	Branded products business	Ukraine	100.00	100.00	165	165	165	165	-	-
Total							62,379	59,923	-	300,000
<i>Indirect subsidiaries (investment through Mega Lifesciences PTY Limited)</i>										
Mega Lifesciences (Australia) Pty. Limited	Branded and OEM products business	Australia	99.99	99.99	468,294	429,442	468,700	429,726	-	-
Mega Lifesciences (Vietnam) Limited	Branded products and distribution business	Vietnam	99.99	99.99	107,959	107,959	108,771	108,527	-	-
Mega Lifesciences Sdn.Bhd	Branded products business	Malaysia	99.99	99.99	17,214	17,214	17,452	17,381	-	-
PT Mega Lifesciences	Branded products business	Indonesia	98.99	98.99	15,163	15,163	15,012	15,012	-	-

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

	Type of business	Country of incorporation	Ownership interest		Paid-up capital		Cost		Dividend income	
			31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 December 2014	31 March 2015	31 March 2014
			(%)				(in thousand Baht)			
Mega Lifesciences PTY Limited	Branded products and distribution business	Cambodia	99.99	99.99	15,281	15,281	15,877	15,698	-	-
Mega Lifesciences Nigeria Limited	Branded products and distribution business	Nigeria	99.99	99.99	14,885	14,885	15,386	15,269	-	-
Mega Lifesciences Ghana Limited	Branded products business	Ghana	99.99	99.99	9,469	9,469	9,589	9,553	-	-
Mega Lifesciences Private Limited	Branded products business	India	99.99	99.99	4,777	4,777	5,254	5,111	-	-
Mega Lifesciences Limited	Distribution business	Myanmar	99.99	99.99	2,534	2,534	4,401	4,200	-	-
E-Sense Limited	Software design, development and other services business	Thailand	99.96	99.96	500	500	499	499	-	-
Mega Products (Mauritius) Limited	Distribution business	Mauritius	99.99	99.99	410	410	1,174	945	-	-
Mega Lifesciences Pte. Ltd.	Distribution business	Singapore	99.99	99.99	156	156	156	156	-	-
Mega Lifesciences PTY Peru S.A.C.	Branded products business	Peru	99.99	99.99	100	100	337	349	-	-
Total							662,608	622,426	-	-

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

8 Property, plant and equipment

Acquisitions, disposals and transfers of property, plant and equipment during the three-month periods ended 31 March 2015 and 2014 were as follows:

<i>Three-month period ended 31 March</i>	Consolidated financial statements			
	2015		2014	
	Acquisitions and transfers in - at cost	Disposals and transfers out - net book value	Acquisitions and transfers in - at cost	Disposals and transfers out - net book value
	<i>(in thousand Baht)</i>			
Land	37,455	-	-	-
Building and building improvements	6,247	-	78,612	-
Leasehold improvements	1,724	101	1,447	-
Machinery and equipment	39,459	-	189,271	-
Furniture, fixtures and office equipment	5,612	135	7,604	69
Vehicles	120	2,893	11,901	2
Assets under construction	4,700	-	33,799	265,369
Exchange difference	(35,224)	37,731	7,010	-
Total	60,093	40,860	329,644	265,440

<i>Three-month period ended 31 March</i>	Separate financial statements			
	2015		2014	
	Acquisitions and transfers in - at cost	Disposals and transfers out - net book value	Acquisitions and transfers in - at cost	Disposals and transfers out - net book value
	<i>(in thousand Baht)</i>			
Building and building improvements	4,984	-	77,948	-
Machinery and equipment	33,475	-	187,846	-
Furniture, fixtures and office equipment	1,300	-	1,799	-
Vehicles	47	-	-	-
Assets under construction	4,700	37,731	33,799	265,369
Total	44,506	37,731	301,392	265,369

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

9 Deferred tax

Deferred tax assets and liabilities as at 31 March 2015 and 31 December 2014 were as follows:

	Consolidated financial statements			
	Assets		Liabilities	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>			
Total	277,152	283,875	(183,751)	(193,336)
Set off of tax	(181,568)	(190,459)	181,568	190,459
Net deferred tax assets (liabilities)	95,584	93,416	(2,183)	(2,877)

	Separate financial statements			
	Assets		Liabilities	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>			
Total	33,724	29,983	(8,647)	(8,681)
Set off of tax	(8,647)	(8,681)	8,647	8,681
Net deferred tax assets	25,077	21,302	-	-

Deferred tax assets arising from accounts receivable relate to export of finished goods from Thailand to other countries for which tax becomes payable upon export of the goods but for which revenue is recognised in the statement of income subsequently at the moment the goods are sold to third parties outside the Group. Deferred tax liabilities arising from inventories also relate to export of finished goods for which the cost becomes deductible for tax upon export but for which the cost of sales is recognised in the statement of income at the moment the goods subsequently are sold to third parties outside the Group.

Movements in total deferred tax assets and liabilities during the three-month periods ended 31 March 2015 and 2014 were as follows:

	Consolidated financial statements			
	At 1 January 2015	(Charged) / Credited to:		At 31 March 2015
		profit or loss (Note 14)	Exchange differences	
	<i>(in thousand Baht)</i>			
Deferred tax assets				
Accounts receivable	243,339	(9,225)	(50)	234,064
Provision for employee benefits	15,872	3,519	(322)	19,069
Loss carry forward	22,157	1,360	(1,582)	21,935
Others	2,507	(366)	(57)	2,084
Total	283,875	(4,712)	(2,011)	277,152
Deferred tax liabilities				
Inventories	189,920	(8,840)	-	181,080
Property, plant and equipment	3,416	(95)	(650)	2,671
Total	193,336	(8,935)	(650)	183,751
Net	90,539	4,223	(1,361)	93,401

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

	Consolidated financial statements			
	At 1	(Charged) /		At 31
	January	Credited to:	Exchange	March
	2014	profit or loss	differences	2014
		(Note 14)		
		(in thousand Baht)		
Deferred tax assets				
Accounts receivable	245,138	16,482	-	261,620
Provision for employee benefits	14,989	468	96	15,553
Loss carry forward	25,826	9,054	601	35,481
Others	2,614	(1,279)	(31)	1,304
Total	288,567	24,725	666	313,958
Deferred tax liabilities				
Inventories	204,658	7,757	-	212,415
Property, plant and equipment	7,621	(654)	133	7,100
Total	212,279	7,103	133	219,515
Net	76,288	17,622	533	94,443
		Separate financial statements		
		(Charged) /		
	At 1	Credited to :		At 31
	January	profit or loss		March
	2015	(Note 14)		2015
		(in thousand Baht)		
Deferred tax assets				
Accounts receivable		21,324	271	21,595
Provision for employee benefits		8,539	3,345	11,884
Others		120	125	245
Total		29,983	3,741	33,724
Deferred tax liabilities				
Inventories		8,681	(34)	8,647
Total		8,681	(34)	8,647
Net		21,302	3,775	25,077

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

	Separate financial statements		
	At 1 January 2014	(Charged) / Credited to : profit or loss (Note 14)	At 31 March 2014
<i>(in thousand Baht)</i>			
Deferred tax assets			
Accounts receivable	20,224	(1,269)	18,955
Provision for employee benefits	7,727	188	7,915
Others	185	(89)	96
Total	28,136	(1,170)	26,966
Deferred tax liabilities			
Inventories	10,149	(1,853)	8,296
Total	10,149	(1,853)	8,296
Net	17,987	683	18,670

10 Trade accounts payable

	<i>Note</i>	Consolidated financial statements		Separate financial statements	
		31 March 2015	31 December 2014	31 March 2015	31 December 2014
<i>(in thousand Baht)</i>					
Related parties	3	-	-	30,829	21,108
Other parties		1,410,209	1,403,926	120,738	133,380
Total		1,410,209	1,403,926	151,567	154,488

11 Warrants

Employee Stock Option Plan

At the extra ordinary general meeting of Shareholders held on 7 June 2013, the shareholders approved the issue and offering of warrants to purchase ordinary shares of the Company to full-time employees at assistant manager level or above of the Group. The Group communicated terms and conditions of the scheme to the employees during June 2014.

Significant descriptions of the Employee Stock Option Plan

Securities type	Warrants to purchase the ordinary shares of the Company
Qualifications of employees eligible for warrants	Full-time employees, at level of assistant manager or above of the Company, its subsidiaries and/or affiliates on or after the date the date on which the issuance and offering of warrants is announced, including those who have been transferred or seconded to any other company while continuing to be employed by the Company, its subsidiaries and/or affiliates.
Type of warrants	Warrants with specified name and non-transferable unless otherwise transferred in accordance with the terms and conditions of the warrants

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Term	Not exceeding 5 years from the date of issuance of the warrants
Grant date	6 June 2014
Number of warrants issued	8,652,400 units
Offer price per unit	Baht 0 (zero Baht)
Exercise ratio	1 unit of warrant per 1 ordinary share, subject to change according to the conditions for adjustment of rights as prescribed under the terms and conditions of the warrants.
Exercise price	Baht 17.50 per share which is equivalent to the IPO price.
Exercise period	On the last day of each month of the 6 month period commencing from the end of 4th year 6 month anniversary
Fair value of warrants	8.35 Baht per unit

The Group measured fair value of options using Black-Scholes model based on number of employees in employment on the reporting date to whom warrants have been awarded with the assumption that all of the option will be exercised at the exercisable period. The Group measured volatility based on three-month historical volatility per month extrapolated to 12 months.

Principal assumptions for options fair-value valuation are as follows:

Ordinary share price per share (Baht)	22.25
Exercise price per option (Baht)	17.50
Expected volatility	28.25%
Options term life (Years)	5
Expected dividend per share (Baht)	0.18
Risk-free interest rate	3.09%

The Group recorded the transaction for the employee stock option plan as follows:

	Consolidated		Separate	
	financial statements	financial statements	financial statements	financial statements
	2015	2014	2015	2014
	<i>(in thousand Baht)</i>			
<i>Statement of financial position as at 31 March 2015/ 31 December 2014</i>				
Investments in subsidiaries	-	-	10,052	7,596
Warrants	(11,244)	(8,431)	(11,244)	(8,431)
<i>Statement of comprehensive income for the three-month periods ended 31 March</i>				
Administrative expenses	2,813	-	357	-

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

12 Corporate social responsibility reserve

The directors approved the appropriation up to maximum of 2% of its consolidated profit after tax to support its corporate social responsibility activities. The Group recorded corporate social responsibility reserve during the three-month period ended 31 March 2015 of Baht 2.1 million in the consolidated and the separate financial statements respectively. During the three-month period ended 31 March 2015, the Company donated an amount of Baht 0.5 million to Mechai Pattana School and reduced such amount from the corporate social responsibility reserve in the consolidated and the separate statements of changes in equity.

13 Segment information

The Group comprises the following segment information:

Segment 1	Brands
Segment 2	Distribution
Segment 3	OEM (“Original Equipment Manufacture”)

“Brands” represents a business segment in which goods are manufactured and sold under brands owned by the Group.

“Distribution” represents a service business segment in which the Group provides logistical and marketing services for goods trading purpose and sale of goods manufactured by third parties.

“OEM” represents a business segment in which goods are manufactured for third parties under brands not owned by the Group.

Information regarding the results of each reportable segment is included below. Performance is measured based on segment profit before tax, as included in the internal management reports that are reviewed by the Group’s CODM. Segment profit before tax is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

Inter-segment charge

The distribution segment provides service to the brand segment in which the inter-segment pricing is determined on an arm’s length basis.

Segment profit before tax

The segment profit before tax is derived from reportable segment revenue minus allocated cost for each segment and inter-segment charges.

Segment assets and liabilities

Segment assets and liabilities are based on the allocation to each segment of the assets and liabilities which are used for the operations of each segment.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Information about reportable segments:

<i>Three-month period ended 31 March</i>	Brand		Distribution		OEM		Total	
	2015	2014	2015	2014	2015	2014	2015	2014
	<i>(in thousand Baht)</i>							
External revenue	876,521	766,975	822,978	840,746	104,123	97,530	1,803,622	1,705,251
Inter-segment revenue	(33,195)	(28,872)	33,195	28,872	-	-	-	-
Other income	2,852	2,463	1,668	902	-	147	4,520	3,512
Total segment revenue	846,178	740,566	857,841	870,520	104,123	97,677	1,808,142	1,708,763
Segment profit before income tax	155,796	79,304	48,641	53,660	15,625	7,480	220,062	140,444
Segment assets as at 31 March/ 31 December	1,960,480	2,221,155	1,760,196	1,579,786	195,264	149,980	3,915,940	3,950,921

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

Reconciliation of reportable segment profit or loss and assets

<i>Three-month period ended 31 March</i>	2015	2014
	<i>(in thousand Baht)</i>	
Profit or loss		
Total profit for reportable segments	220,062	140,444
Unallocated amounts:		
Other corporate expenses	(67,276)	(48,991)
Depreciation and amortisation	(35,410)	(31,459)
Finance costs	(2,495)	(4,838)
Investment income	7,964	4,568
Other income	2,839	984
Income tax expense	(19,213)	(4,167)
Consolidated profit	106,471	56,541
	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>	
Assets		
Total assets for reportable segments	3,915,940	3,950,921
Other unallocated amounts	2,820,416	2,780,931
Consolidated total assets	6,736,356	6,731,852

14 Income tax expense

Income tax recognised in profit or loss

<i>Three-month period ended 31 March</i>	<i>Note</i>	Consolidated financial statements		Separate financial statements	
		2015	2014	2015	2014
<i>(in thousand Baht)</i>					
Current tax expense					
Current year		23,819	22,322	7,799	6,000
Adjustment for prior years		(383)	-	-	-
		23,436	22,322	7,799	6,000
Deferred income tax					
Movements in temporary differences	9	(4,223)	(18,155)	(3,775)	(683)
Total income tax expense		19,213	4,167	4,024	5,317

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

The current tax expense in the consolidated and separate statements of comprehensive income are different from the amount determined by applying the Thai corporation tax rate to the accounting profit for the period principally because:

- (a) a significant portion of the Group's profit was derived from promoted activities which are not subject to tax.
- (b) of the different treatment for accounting and taxation purposes of certain items of income/expense, in particular, allowance for obsolescence and temporally difference arising from revenue and cost of sale of export of finished goods from Thailand to other countries for which tax becomes payable upon export of the goods but for which revenue and cost of sale are recognised in the statement of income subsequently at the moment the goods are sold to third parties outside the Group.

15 Earnings per share

The calculations of basic earnings per share for the three-month periods ended 31 March 2015 and 2014 were based on the profit for the periods attributable to ordinary shareholders of the Company and the number of ordinary shares outstanding during the periods as follows:

	Consolidated		Separate	
	financial statements		financial statements	
<i>Three-month period ended 31 March</i>	2015	2014	2015	2014
	<i>(in thousand Baht / thousand shares)</i>			
Profit for the period attributable to ordinary shareholders of the Company	<u>106,487</u>	<u>56,578</u>	<u>98,307</u>	<u>380,029</u>
Weighted average number of ordinary shares outstanding	<u>865,249</u>	<u>865,249</u>	<u>865,249</u>	<u>865,249</u>
Basic and diluted earnings per share (in Baht)	<u>0.12</u>	<u>0.07</u>	<u>0.11</u>	<u>0.44</u>

The Company registered the increase in shares with the Department of Business Development, the Ministry of Commerce on 17 July 2013, and the total authorised capital is Baht 436,950,941 comprising of 873,901,882 shares with a par value of Baht 0.50 per share. 8,652,400 shares of which are related to warrants under Employee Stock Option Plan (note 11).

Diluted earnings per share

During the year 2014, the Company issued the warrants for employees, the issue of warrants (note 11) does not have the dilutive effect on the earnings per share calculation because the fair value of the service yet to be rendered together with the exercise prices exceeds the average market price of ordinary share during the financial period.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

16 Commitments and contingent liabilities with non-related parties

	Consolidated financial statements		Separate financial statements	
	31 March 2015	31 December 2014	31 March 2015	31 December 2014
	<i>(in thousand Baht)</i>			
Capital commitments				
Contracted but not provided for:				
Land	94,080	129,074	94,080	94,080
Buildings and other constructions	27,659	24,414	27,659	22,331
Total	121,739	153,488	121,739	116,411
Non-cancellable operating lease commitments				
Within one year	34,279	19,447	6,408	7,812
After one year but within five years	35,274	12,913	300	1,200
Total	69,553	32,360	6,708	9,012
Other commitments				
Purchase orders for goods and supplies	116,053	166,099	116,053	166,099
Bank guarantees	62,455	63,108	62,455	61,108
Total	178,508	229,207	178,508	227,207

Operating lease agreements

The Group has various operating lease agreements for office and warehouse rental. The period of agreements is variable from 1-5 years.

Distribution and service agreements

The Group has entered into usually exclusive distribution and service agreements with third parties in various countries. The compensation for the distributors is variable and depends on the volume of business carried out. The compensation accruing to the Group is usually fixed and revised periodically. The agreements can usually be terminated within a year without the Group incurring significant obligations.

Contingent liabilities

As at 31 March 2015, the Company had contingent liabilities with financial institutions to guarantee the Company's subsidiaries in respect of line of credit use for amounts up to Baht 1,340 million and U.S. Dollars 13 million (*31 December 2014: Baht 1,340 million and U.S. Dollars 13 million*).

17 Events after the reporting period

At the Annual General Meeting of the shareholders of the Company held on 10 April 2015, the shareholders approved the appropriation of dividends of Baht 0.25 per share, amounting to Baht 216.3 million. The dividends were paid to shareholders during April 2015.

Mega Lifesciences Public Company Limited and its Subsidiaries
Notes to the interim financial statements
For the three-month period ended 31 March 2015 (Unaudited)

18 Reclassification of accounts

Certain accounts in the 2014 financial statements have been reclassified to conform to the presentation in the 2015 financial statements. The significant reclassifications were as follows:

	2014					
	Consolidated financial statements			Separate financial statements		
	Before reclass.	Reclass.	After reclass. <i>(in thousand Baht)</i>	Before reclass.	Reclass.	After reclass.
<i>Statement of financial position</i>						
Advance to suppliers and distributors	119,254	9,413	128,667	-	-	-
Accrued expenses	(356,829)	<u>(9,413)</u>	(366,242)	-	<u>-</u>	-
		<u>-</u>			<u>-</u>	
<i>Statement of comprehensive income</i>						
Investment income	-	4,568	4,568	303,373	3,079	306,452
Finance costs	(270)	<u>(4,568)</u>	(4,838)	-	<u>(3,079)</u>	(3,079)
		<u>-</u>			<u>-</u>	

The reclassifications have been made because, in the opinion of management, the new classification is more appropriate to the Group's business.